Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at Reducing Alcohol Consumption

If you developed a drinking problem during the pandemic, you’re not alone. Alcohol use disorder (AUD) affects 283 million people and growing, which is why Psilera Inc. is studying psilocybin’s anti-addictive properties.

The Florida biotech company launched a new preclinical study that will assess up to seven psychedelic-inspired new chemical entities (NCE) on reducing alcohol consumption. The company aims to limit the psychedelic effects of the drugs to potentially allow administration outside of a clinical setting.

PDF of article